Author

Feng Tian

Institution: Ambrx (United States)

Observed institution: Ambrx (United States)

ORCID: 0009-0002-5173-4269

Observed ORCID: 0009-0002-5173-4269

OpenAlex ID: A5101334883

Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody–Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer

2024 · Lillian K. Skidmore, David Mills, et al. · Molecular Cancer Therapeutics · 24

Data from Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody–Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer

2024 · Lillian K. Skidmore, David Mills, et al.

Table S1 from Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody–Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer

2024 · Lillian K. Skidmore, David Mills, et al.

Works count: 3

Citation count: 24

H-index: 1

I10-index: 1